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ABSTRACT
Hypopharyngeal invasion would be a key finding in determining the extent of the irradiation fields in patients with cer-
vical esophageal squamous cell carcinoma (CESCC). This study aimed to investigate the clinical outcomes of chemora-
diotherapy using simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) omitting upper cervical
lymph nodal irradiation in CESCC without hypopharyngeal invasion, and the dosimetric superiority of SIB-IMRT to
3D conformal radiotherapy (3DCRT). We retrospectively identified 21 CESCC patients without hypopharyngeal inva-
sion [clinical Stage I/II/III/IV (M1LYM); 3/6/5/7] (UICC-TNM 7th edition) who underwent chemoradiotherapy
using SIB-IMRT between 2009 and 2015. SIB-IMRT delivered 60 Gy to each primary tumor and the metastatic lymph
nodes, and 48 Gy to elective lymph nodal regions, including Levels III and IV of the neck, supraclavicular, and upper
mediastinal lymphatic regions, in 30 fractions. The overall survival rate, locoregional control rate, and initial recurrence
site were evaluated. 3DCRT plans were created to perform dosimetric comparisons with SIB-IMRT. At a median
follow-up of 64.5 months, the 5-year locoregional control and overall survival rates were 66.7% and 53.4%, respectively.
Disease progressed in eight patients: all were locoregional progressions and no patients developed distant progression
including upper cervical lymph nodal regions as initial recurrence sites. The planning study showed SIB-IMRT
improved target coverage without compromising the dose to the organs at risk, compared with 3DCRT. In conclusion,
omitting the elective nodal irradiation of the upper cervical lymph nodes was probably reasonable for CESCC patients
without hypopharyngeal invasion. Locoregional progression remained the major progression site in this population.
Keywords: cervical esophageal squamous cell carcinoma; radiotherapy; intensity-modulated; chemoradiother-
apy; planning study
INTRODUCTION
Chemoradiotherapy using the 3D conformal radiotherapy
(3DCRT) technique yields a 29–66.5% 3-year overall survival (OS)
rate in patients with cervical esophageal squamous cell carcinoma
(CESCC) [1–5]. Two reports have suggested that this outcome is
comparable with that for patients treated with surgery [6, 7].
However, locally advanced CESCC continues to show poor locore-
gional control (LRC) and OS [3–5]. One of the reasons for poor
clinical outcome for locally advanced CESCC is the inadequate
dose delivery to target organs using 3DCRT because of its technical
limitations. Unlike 3DCRT, intensity-modulated radiotherapy
(IMRT) is an advanced radiotherapy technique, which delivers con-
formal doses to the target but reduces doses to the spinal cord [8].
IMRT for CESCC has been reported as yielding better clinical out-
come than that achieved with 3DCRT [9, 10].
© The Author(s) 2019. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which







/jrr/advance-article-abstract/doi/10.1093/jrr/rrz019/5488782 by Kyoto U
niversity user on 12 June 2019
The cervical esophagus is serially connected to the hypopharynx.
Hypopharyngeal invasion of CESCC is not a rare situation and
occurs in 11.1–42.6% of CESCC patients treated with chemora-
diotherapy [5, 11–14]. The hypopharyngeal submucosa has abun-
dant lymphatic drainage to the cervical lymph nodal regions. Once
CESCC invades the hypopharynx, the risk of metastasis to the
upper cervical lymph nodal regions (Level II and retropharyngeal
lymph nodes) increases: 12% in CESCC patients with hypopharyn-
geal invasion vs 0–1% in CESCC patients without hypopharyngeal
invasion, respectively [15–17]. Those pathophysiologic backgrounds
suggest that the irradiation fields for the upper cervical lymph nodal
regions are safely spared for CESCC without hypopharyngeal inva-
sion. However, previous planning studies [8–10, 12–14, 18] did not
consider the presence or absence of hypopharyngeal invasion in set-
ting the extent of the irradiation fields, except for one study [11].
To our knowledge, no information is available on the clinical out-
come of IMRT, and its dosimetric evaluation, for CESCC patients
without hypopharyngeal invasion.
As of 2009, in our institution, CESCC patients without hypo-
pharyngeal invasion underwent definitive chemoradiotherapy using
simultaneous integrated boost intensity-modulated radiotherapy
(SIB-IMRT). SIB-IMRT adopted elective nodal irradiation (ENI)
omitting the upper cervical lymph nodal regions. In this study, we
retrospectively reviewed the medical records of these patients and
performed a planning study to compare SIB-IMRT with 3DCRT
using ENI omitting the upper cervical lymph nodal regions. We
aimed to examine the safety and effectiveness of chemoradiotherapy
using SIB-IMRT to CESCC without hypopharyngeal invasion, omit-
ting upper cervical lymph nodal irradiation, and carry out a dosimet-
ric evaluation of SIB-IMRT.
MATERIALS AND METHODS
Inclusion criteria
This study retrospectively reviewed the medical records of patients
who underwent SIB-IMRT for CESCC in our institution. All
patients gave written informed consent for the research use of their
clinical data prior to treatment. This study was reviewed and
approved by the Institutional Review Board in our institution on 27
July 2016 (R0681) and on 16 March 2017 (R1048), and it was con-
ducted in accordance with the Declaration of Helsinki and the
Japanese Ethical Guidelines for Epidemiological Research.
From May 2009 to March 2015, 31 consecutive patients under-
went definitive chemoradiotherapy using SIB-IMRT for CESCC in
our institution. Among them, 21 patients met the following criteria:
(i) histologically confirmed squamous cell carcinoma, (ii) the pri-
mary tumor was located in the cervical esophagus without hypo-
pharyngeal invasion, (iii) there was a prescription of >50 Gy to the
primary tumor and metastatic lymph nodes, and (iv) chemotherapy
was concurrently administered. Ten patients were excluded from
this study because of the following reasons: hypopharyngeal inva-
sion (n = 8), non-use of chemotherapy (n = 1), and adenocarcin-
oma (n = 1).
This study collected the following information from the patients’
medical records: age, sex, Eastern Cooperative Oncology Group
performance status, laboratory data, clinical stage of carcinoma
(Union for International Cancer Control TNM Classification of
Malignant Tumors, 7th edition), resectability, details of radiotherapy
and chemotherapy, radiological findings [including computed tom-
ography (CT) of the neck, chest and abdomen; magnetic resonance
imaging of the neck and upper mediastinum; and 18F-
fluorodeoxyglucose positron emission tomography (FDG-PET)],
gastrointestinal endoscopic findings, and adverse events. Patient
characteristics are listed in Table 1. Tracheal invasion or major ves-
sel involvement of the primary tumor or metastatic lymph nodes
was judged unresectable by the multidisciplinary oncology team
(gastroenterologists, surgeons, medical oncologists, and radiation
oncologists). ‘M1LYM’ indicates patients with supraclavicular and
lower cervical lymph nodal metastasis that was included in the
irradiation fields.
Details of delineation of SIB-IMRT
Delineation was performed in the included 21 patients as follows:
CT simulation was performed with patients immobilized in the
supine position. The primary tumor and metastatic lymph nodes
were delineated based on physical examination, gastrointestinal
endoscopy, and radiological findings. The clinical target volume
(CTV) for the primary tumor (CTVprimary) was created by adding a
0.5 cm margin in the radical direction and a 2.0 cm margin cranio-
caudally of the primary tumor. The CTV for metastatic lymph
nodes (CTVnode) was created by adding a 0.5 cm margin in all
directions from the metastatic lymph nodes. Those CTVs were
manually modified to avoid overlap of bronchi, lungs and bones,
which were considered anatomical barriers to tumor invasion. The
planning target volumes (PTVs) for the primary tumor
(PTVprimary) and the metastatic lymph nodes (PTVnode) were
Table 1. Patient characteristics
Parameters
Median age (IQR) 66 (57, 68)
Sex (female/male) 2/19
ECOG Performance Status (0/1/2) 16/5/0
Clinical stage (I/II/III/IV)a 3/6/5/7
T status (1/2/3/4) 5/5/2/9
N status (0/1/2/3) 5/13/3/0
M status (0/1LYM) 14/7




IQR = interquartile range, ECOG = Eastern Cooperative Oncology Group.
M1LYM means patients with supraclavicular and lower cervical lymph nodal
metastasis included in the irradiation fields. Unresectable status indicates patients
with the tracheal invasion or major vessel involvement of the primary tumor or
metastatic lymph nodes.
aClassification of clinical stage was based on the Union for International Cancer
Control TNM Classification of Malignant Tumors, 7th edition.
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created by adding a 0.5 cm margin in all directions to the
CTVprimary and the CTVnode, respectively. The PTV60 was created
from the sum of the PTVprimary and the PTVnode. All patients
underwent ENI. The CTVENI included the lymph node region from
Level IIIs and IV of the neck, supraclavicular, and upper mediastinal
lymphatic lesions to 1–3 cm caudally from the carina of the trachea.
Then, the PTVENI was created by adding a 0.5 cm margin in all
directions to the CTVENI, excluding the volume overlapping with
the PTV60. Moreover, the PTV60 and the PTVENI were cropped at
0.3 cm below the skin surface. The organs at risk (OARs) were deli-
neated for the spinal cord, bilateral lungs, thyroid gland, and bra-
chial plexus. The spinal cord plus a 0.3 cm margin formed the
planning OAR volume (PRVcord). To evaluate the doses to the thy-
roid gland outside of the PTV60, we defined the thyroidout of PTV as
excluding the volume of overlap between the PTV60 and the thyroid
gland. To evaluate the doses to the thyroid gland outside of the
PTV60, we defined the thyroidout of PTV as excluding the volume
of overlap between the PTV60 and the thyroid gland from the thy-
roid gland.
Details of dose prescription and optimization of SIB-
IMRT
Treatment plans were created using the SIB-IMRT method. The
prescribed dose was 60 Gy to the PTV60 and 48 Gy to the PTVENI
in 30 fractions. Optimizations were performed for prescribing a
dose of 60 Gy as D50% (Dx% represents the dose covering x% of the
structure volume) of the PTV60 for eight patients from May 2009
to March 2011 and D95% of the PTV60 for 13 patients from April
2011 to March 2015. Then, the included 21 patients underwent
SIB-IMRT 5 days per week. The median overall treatment time was
42 days [interquartile range (IQR), 42–43]. The median total dose
to the PTV60 and the PTVENI were 60 Gy (IQR, 60–60) and 48 Gy
(IQR, 48–51), respectively.
SIB-IMRT plans used 4 or 6 MV photon beams. Seven to nine
static coplanar fields were used in 19 patients from May 2009 to
March 2014. We manually fixed the caudal jaw position in two lat-
eral fields to the level of the top of the lungs to reduce the lung
doses. From April 2014, volumetric-modulated arc therapy using
coplanar two arcs was used for two patients. One arc rotated
clockwise from 181° to 179°, and the other rotated counterclock-
wise from 179° to 181°. Avoidance sectors were introduced for bilat-
eral 75° gantry angles for each arc to reduce lung doses. Avoidance
sectors allowed the gantry to rotate with zero monitor unit output at
preset angles (RapidArc system; Varian Medical Systems, Palo Alto, CA,
USA).
We used dose constraints for the PTV60 as follows: D2% <72 Gy,
D98% >55.8 Gy, and D50% < 63 Gy; and for the PTVENI as follows:
D98% > 45.9 Gy, D50% < 51Gy, and D2% < 60 Gy. The dose con-
straints for the OARs were also defined for the spinal cord and bilateral
lungs as follows: PRVcord for maximum point dose < 50 Gy, D2 cm3
(Dx cm3 represents the dose covering x cm
3 of the structure volume)
< 46 Gy, and the lung V10 Gy (Vx Gy represents the volume receiving
x Gy) < 50%, V15 Gy < 40%, and V20 Gy < 25%. We did not set any
dose constraints for the thyroidout of PTV or the brachial plexus.
Dose calculation of SIB-IMRT
Three types of dose calculation algorithms were used for the moni-
tor unit settings, along with updates of the treatment planning sys-
tems and machine calibration as follows: pencil beam convolution
version 8.2.23 (n = 2)/version 8.6.15 (n = 9), anisotropic analytical
algorithm version 8.6.15 (n = 3)/version 11.0.31 (n = 2), and
Acuros XB version 11.0.31 (n = 5). The dose distributions were cal-
culated with a 2.5-mm grid size and included a heterogeneity correc-
tion (Batho Power Law method; Eclipse treatment planning system,
Varian Medical Systems, Palo Alto, California, USA).
Details of chemotherapy
Chemotherapy was administered twice every 4 weeks during radio-
therapy. Nineteen patients received cisplatin (70 mg/m2 per day)
by slow drip on Days 1 and 29, and 5-fluorouracil (700 mg/m2 per
day) by continuous infusion for 24 h on Days1–4 and 29–32. One
patient received only cisplatin (80 mg/m2 per day) by slow drip on
Days 1 and 29 because of alcoholic cirrhosis, and another patient
received only 5-fluorouracil (700 mg/m2 per day) by continuous
infusion for 24 h on Days 1–4 and 29–32 because of advanced age.
Follow-up
Initial evaluation of the tumor response was performed with endos-
copy and CT 4–6 weeks after the last day of radiotherapy.
Endoscopy was repeated every month until complete response or
recurrence was confirmed. After complete response was confirmed,
endoscopy and CT were repeated every 3–6 months. When it was
difficult to judge recurrences with CT alone, FDG-PET was used.
In addition to endoscopy and CT, physical examination and blood
sampling were performed at each follow-up.
End point of clinical outcome
LRC and OS rates were estimated with the Kaplan–Meier method.
Survival was measured from the initial day of radiotherapy to the
date of the last follow-up or death from any cause. We categorized
the initial recurrence site into three types: locoregional progression,
distant metastasis, and both. Locoregional progression was defined
as progression of the primary tumor or metastatic lymph nodes and
regional lymph nodal metastasis inside the irradiation fields.
Metachronous superficial esophageal tumors outside the irradiation
fields were not counted as locoregional progression events. Distant
metastasis was defined as non-regional lymph nodal metastasis
excluding supraclavicular lymph node or distant organ metastasis.
Simultaneous development of locoregional progression and distant
metastasis was categorized as both. The LRC rate was calculated
from the initial day of radiotherapy to the day of locoregional pro-
gression. Adverse events were retrospectively evaluated using
Common Terminology Criteria for Adverse Events, version 4.0.
Adverse events within 90 days after the initial day of radiotherapy
were defined as acute adverse events, and those occurring 91 days
or more after initial day of radiotherapy were defined as late adverse
events.
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3DCRT planning
We created 3DCRT plans for all patients in order to compare the
dose–volume indices of the 3DCRT plans and the SIB-IMRT plans
that were used clinically [19]. The 3DCRT plans were created using
the cone-down method and the same target volume used in the
SIB-IMRT plans, by two board-certified radiation oncologists in the
author group: one created all the 3DCRT plans, and the other one
confirmed them. Neither of these radiation oncologists were
involved in the SIB-IMRT planning. To avoid bias, they did not
refer to the SIB-IMRT plans during 3DCRT planning. The 3DCRT
planning was completed before starting the analysis of the SIB-
IMRT plans. Initially, anterior–posterior plus parallel oblique radi-
ation fields were used up to a total dose of 40 Gy, with 2.0 Gy frac-
tions per day, which covered the PTV60 and the PTVENI and a
0.5 cm leaf margin in all directions. Boost irradiation was applied to
the PTV60 using three to four coplanar fields, and the dose of the
boost irradiation was 20 Gy, at a 2.0 Gy fraction per day. Although
the leaf margin was set to 0.5 cm in all directions, reducing the leaf
margin in the direction of the spinal cord was often necessary to
reduce the dose to the spinal cord. Doses were prescribed to the
isocenter in both the initial and boost plans.
Dosimetric comparison between SIB-IMRT and 3DCRT
We used two types of dose prescription. We categorized the
patients who underwent SIB-IMRT into two groups: those with a
prescribed dose of 60 Gy delivered to 50% of the PTV60 (SIB-
IMRT-D50%), and those with a prescribed dose of 60 Gy delivered
to 95% of the PTV60 (SIB-IMRT-D95%). To compare the coverage
of the gross tumor and OARs between two types of SIB-IMRT and
3DCRT, we created the dose–volume histograms of the PTV60,
bilateral lungs, PRVcord, thyroidout of PTV and brachial plexus. Then,
we calculated the D98%, D50%, D2%, homogeneity index (HI) and
conformation number (CN) of the PTV60, V10 Gy, V15 Gy and
V20 Gy of the bilateral lungs; the maximum dose and D2 cm3 of the
PRVcord, V50 Gy and V60 Gy; the mean dose of the thyroidout of PTV,
V60 Gy and D2 cm3 of the brachial plexus; and the maximum dose and
D2 cm3 of the Vout of PTV, using each method. The HI was obtained
using the following formula: HI = (D2% – D98%)/D50% [20]. The HI
value should be more than 0 and as close to 0 as possible. The CN
was defined as CN = (TVRI/TV) × (TVRI/VRI) [21]. TVRI, TV and
VRI represent the volume of the PTV receiving 60 Gy, the volume of
the PTV, and the total volume receiving 60 Gy, respectively. The
maximum value for the CN is 1: the closer the CN to 1, the better
the conformity.
Statistical analysis
Differences in OS and LRC rates between the categorized variable
[age (≤66 vs >66), sex (male vs female), performance status (0 vs 1),
T status (T1–3 vs T4), N status (N0 vs N1–2), M status (M0 vs
M1LYM), resectability (resectable vs unresectable), and the types of
the dose prescription (SIB-IMRT-D95% vs SIB-IMRT-D50%)] were
analyzed using the log-rank test. To evaluate the dosimetric differences
between the two types of SIB-IMRT and 3DCRT, we used the
Kruskal–Wallis test to compare the dose–volume indices of the
PTV60, bilateral lungs, PRVcord, thyroidout of PTV, brachial plexus, and
Vout of PTV. All statistical tests were two-sided and carried out using
EZR version 1.36 (Saitama Medical Center, Jichi Medical University,
Saitama, Japan) [22], which is a graphical user interface for R
(R Foundation for Statistical Computing, Vienna, Austria, version
3.0.2), and a P-value of <0.05 was considered to indicate statistical sig-
nificance. More precisely, EZR is a modified version of R commander
used to facilitate biostatistics.
RESULTS
OS, LRC, and initial recurrence sites
The median follow-up for all patients was 35 (range, 4–95) months,
and the median follow-up for censored patients was 64.5 (range,
28–95) months. The 3- and 5-year OS rates were 60.0% and 53.4%,
respectively, and the 3- and 5-year LRC rates were 66.7% and
66.7%, respectively (Fig. 1A).
Nine patients were dead at the time of analysis due to esopha-
geal cancer progression (n = 6), other malignant tumors (n = 2),
and sudden death (n = 1). Disease progressed in eight patients, and
all initial recurrence sites were locoregional progression. That is,
seven locoregional progressions occurred in the tumor beds of the
the primary tumor or the metastatic lymph nodes, and the other
was in the region of the ENI. Distant progression including upper
cervical lymph nodal metastasis was not observed as the initial
recurrence site. Metachronous superficial esophageal tumors were
detected in three patients at 31, 47 and 52 months after the initial
day of radiotherapy. All metachronous superficial esophageal tumors
were outside the irradiation fields and completely resected by endo-
scopic treatment.
Univariate analysis
M1LYM and unresectable statuses were associated with poor OS
rate (P = <0.001 and 0.009). The 5-year OS rate was 72.7% for
patients with M0 status vs 14.3% for patients with M1LYM status
(Fig. 1B), and 88.9% for patients with resectable status vs 27.3% for
patients with unresectable status (Fig. 1C). Other factors not asso-
ciated with OS were age (P = 0.85), sex (P = 0.29), PS (P = 0.31),
T status (P = 0.14), N status (P = 0.25), and the types of the dose
prescription (P = 0.36).
Unresectable status was associated with a poorer LRC rate (P = 0.004)
(Fig. 1D). The 5-year LRC rate was 90.0% for patients with resect-
able status vs 45.5% for patients with unresectable status. Other fac-
tors not associated with LRC were age (P = 0.35), sex (P = 0.34),
PS (P = 0.14), T status (P = 0.44), N status (P = 0.095), M1LYM
status (P = 0.053), and the types of the dose prescription (P = 0.11).
Adverse events
Grade 3 or higher acute hematological toxicity occurred in five
patients (5 leukopenia, 2 neutropenia and 1 anemia), and Grade 4
acute hematological toxicity occurred in 1 patient (leukopenia and
neutropenia). Grade 3 acute non-hematological toxicity occurred in
four patients (3 esophagitis, 1 anorexia, 1 esophageal stricture, 1
hyponatremia, 1 decreased renal function and 1 ischemic colitis).
One patient developed a trachea–esophagus–lymph nodal fistula
due to locoregional progression.
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No patient developed late esophageal fistula or pleural effusion
without recurrences. Grade 3 drug-induced interstitial lung disease
was observed in one patient 8 months after the initial day of CRT,
and Grade 3 esophageal stricture without recurrence was observed
in two patients. Grade 3 or higher radiation pneumonitis was not
observed. Grade 2 hypothyroidism was observed in 10 patients.
Dosimetric comparison between 3DCRT and IMRT
Figure 2 shows the representative dose distribution in SIB-IMRT
(Fig. 2A and C) and 3DCRT (Fig. 2B and D), and the mean dose–
volume histograms of all included patients and dose–volume indices
of the PTV60 and the OARs for each method are shown in Fig. 3
and Table 2, respectively. All dose–volume indices of the PTV60 dif-
fered significantly between the three methods (P < 0.001), and the
post hoc analysis showed that SIB-IMRT-D95% provided significantly
better target coverage and target conformity of the PTV60 compared
with 3DCRT (D98%, P < 0.001; D50%, P < 0.001; D2%, P < 0.001;
HI, P = 0.0048; and CN, P < 0.001) and SIB-IMRT-D50% (D98%,
P < 0.001; D50%, P < 0.001; D2%, P = 0.018; HI, P < 0.001; and
CN, P = 0.0015). In addition, there were no significant differences
in the doses to the bilateral lungs and Vout of PTV between the two
types of SIB-IMRT and 3DCRT. The PRVcord and brachial plexus
were safely spared by both types of SIB-IMRT and 3DCRT. Both
types of SIB-IMRT significantly reduced the dose to the thyroid
compared with 3DCRT.
DISCUSSION
The present study focused on the clinical outcome and dosimetric
evaluation of CESCC patients without hypopharyngeal invasion.
Locoregional progression remained the major progression site. No
upper cervical lymph nodal metastasis occurred when omitting ENI
for the upper cervical lymph nodal regions. The toxicity of SIB-
IMRT was similar to that of 3DCRT. SIB-IMRT-D95% for this
population improved the target coverage and the conformity of the
PTV without compromising the dose to the OARs, compared with
3DCRT.
Unresectable CESCC remained the negative prognostic factor
for LRC in the present study. Unresectable status usually involves
bulky or locally advanced esophageal carcinoma. Those factors are
Fig. 1. Kaplan–Meier curves for overall survival and locoregional control rate for all included patients (A), overall survival rate
according to M status (B), and overall survival and locoregional control rate according to resectability (C, D). Abbreviations:
M0 = patients without non-regional lymph nodal metastasis, M1LYM = patients with supraclavicular lymph nodes included in
the irradiation fields, Unresectable = patients with tracheal invasion or major vessel involvement of the primary tumor or
metastatic lymph nodes.
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reported to be associated with poor OS and LRC in thoracic
esophageal squamous cell carcinoma [23] and in CESCC patients
treated with 3DCRT [3]. The present study suggested that SIB-
IMRT-D95% improved target coverage for CESCC. However, this
was probably not enough to improve the clinical outcome for unre-
sectable locally advanced CESCC. Zhao et al. reported that an
intensified radiotherapy regimen, such as a total dose escalation to
>66 Gy and a hypofractionated schedule using >2 Gy per fraction,
improved LRC in CESCC [14]. Further development of the treat-
ment strategy, such as dose escalation and concurrent chemotherapy
regimens, are needed to improve LRC in unresectable CESCC
patients.
Previous studies have reported that upper cervical lymph nodal
metastasis occurs in 4.1–11.1% of patients after chemoradiotherapy
for CESCC [4, 9, 24, 25]. Among these studies, one report
suggested that the incidence of the upper cervical lymph nodal
metastasis after chemoradiotherapy for CESCC depends on the
existence of hypopharyngeal invasion: 4.2% without hypopharyngeal
invasion vs 66.6% with hypopharyngeal invasion [25]. Our finding
was consistent with that report. The present study showed that
upper cervical lymph nodal metastasis was not observed as the ini-
tial recurrence site in CESCC patients without hypopharyngeal
invasion when ENI was omitted for the upper cervical lymph nodal
regions. Although further confirmatory study is necessary, omitting
ENI for the upper cervical lymph nodal regions is probably reason-
able for CESCC patients without hypopharyngeal invasion.
The incidence and severity of the adverse events in SIB-IMRT
for CESCC were similar to those in 3DCRT. A comparison of these
adverse events with those described in previous reports for 3DCRT
are shown in Table 3. In previous reports, the most common Grade
Fig. 2. Axial and coronal images of the dose distribution of (A, C) simultaneous integrated boost intensity-modulated
radiotherapy and (B, D) 3D conformal radiotherapy. Magenta translucent contour: primary tumor; orange translucent
contour: metastatic lymph nodes; red contour: sum of the planning target volume of the primary tumor and the metastatic
lymph nodes.
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3–4 acute hematological and non-hematological adverse events in
CESCC patients treated with chemoradiotherapy using 3DCRT
were leukopenia and esophagitis, respectively [1–4, 12, 25]. Further,
late esophageal stricture occurred in 0–14.7% of patients in previous
reports [1, 2, 4, 9, 12, 24]. Our result suggests that clinically adverse
events when using SIB-IMRT was similar to those resulting when
using 3DCRT. A further three reports compared the toxicity of
3DCRT with that of IMRT and showed there were no significant
differences in the incidence and severity of the adverse events
between them [9, 12, 18]. Our results indicated that SIB-IMRT for
CESCC was a safe radiotherapy technique.
The previous dosimetric planning study comparing IMRT with
3DCRT for CESCC had some flaws in the study design. First, the
extent of ENI varied in each patient depending on the radiation
oncologist [8]. Second, the dose–volume histogram of the lung was
not correctly calculated in the previous report because the volume
of the entire lung was not fully scanned. Contrary to a previous
report, the present study adopted the same extent of ENI and
Fig. 3. Mean cumulative dose–volume histograms of all patients for PTV60 (A), bilateral lungs (B), PRVcord (C), brachial
plexus (D), and Thyroidout of PTV (E). Abbreviations: 3DCRT = 3D conformal radiotherapy, PTV60 = sum of planning target
volume of primary tumor and metastatic lymph nodes, PRVcord = the planning organs-at-risk volume of spinal cord, SIB-
IMRT = simultaneous integrated boost intensity-modulated radiotherapy, SIB-IMRT-D50%: SIB-IMRT with the prescribed
dose of 60 Gy delivered to 50% of PTV60, SIB-IMRT-D95%: SIB-IMRT with the prescribed dose of 60 Gy delivered to 95% of
PTV60, Thyroidout of PTV = volume of thyroid gland excluding the volume overlapping with PTV60.
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Table 2. Comparison of the dose–volume indices of PTV60 and OARs between SIB-IMRT and 3DCRT
Dose index 3DCRT SIB-IMRT-D95% SIB-IMRT-D50% P-value
PTV60
Volume (ml) (IQR) 138.8 (96.8, 188.1)
D98% (Gy) (IQR) 54.3 (51.9, 56.1) 58.9 (57.8, 59.3) 53.7 (53.3, 54.0) <0.001
D50% (Gy) (IQR) 60.4 (60.3, 61.0) 62.4 (61.9, 63.0) 60.1 (59.7, 60.3) <0.001
D2% (Gy) (IQR) 63.5 (62.9, 63.7) 64.8 (64.5, 65.8) 63.1 (62.9, 63.7) <0.001
HI (IQR) 0.135 (0.123, 0.182) 0.115 (0.086, 0.126) 0.155(0.150, 0.165) <0.001
CN (IQR) 0.34 (0.32, 0.39) 0.77 (0.72, 0.79) 0.42 (0.36, 0.45) <0.001
Bilateral lungs
Volume (ml) (IQR) 2866 (2591, 3366)
V10 Gy (%) (IQR) 23.3 (21.5, 26.3) 22.2 (20.2, 24.2) 21.3 (19.7, 24.2) 0.39
V15 Gy (%) (IQR) 17.7 (16.1, 21.7) 17.4 (15.5, 19.3) 16.9 (15.5, 18.2) 0.79
V20 Gy (%) (IQR) 12.6 (11.4, 15.3) 13.7 (12.3, 15.4) 13.4 (12.5, 14.4) 0.51
PRVcord
Volume (ml) (IQR) 137.2 (127.1, 148.5)
Maximum dose (Gy) (IQR) 49.5 (48.8, 49.9) 48.8 (48.4, 49.2) 49.2 (47.3, 51.2) 0.22
D2 cm3 (Gy) (IQR) 46.6 (46.3, 47.2) 44.4 (43.9, 45.4) 45.2 (44.1, 46.8) <0.001
Thyroidout of PTV
Volume (ml) (IQR) 6.6 (3.8, 7.7)
V50 Gy (%) (IQR) 100 (98.7, 100) 99.5 (98.5, 100) 100 (100, 100) 0.02
V60 Gy (%) (IQR) 74.7 (48.3, 79.0) 27.5 (16.4, 33.2) 29.2 (15.9, 48.2) 0.001
Mean dose (Gy) (IQR) 60.5 (59.4, 61.0) 57.6 (56.3, 58.5) 58.4 (57.8,59.9) 0.007
Brachial plexus
Volume (ml) (IQR) 6.6 (5.9, 8.6)
V60 Gy (ml) (IQR) 0 (0, 0) 0 (0, 0.05) 0 (0, 0) Not applicable
D2 cm3 (Gy) (IQR) 49.4 (48.5, 50.4) 49.8 (48.8, 51.4) 51.3 (50.5, 52.7) 0.03
Vout of PTV
Maximum dose (IQR) 64.6 (63.6, 65.1) 65.6 (64.0, 66.6) 64.0 (63.3, 64.7) 0.20
D2 cm3 (IQR) 62.2 (61.8, 63.3) 62.6 (61.9, 63.3) 61.6 (61.1, 62.2) 0.25
3DCRT = 3D conformal radiotherapy, HI = homogeneity index [20], CN = conformity number [21], Dx cm3 = the dose covering x cm
3 of the structure volume,
Dx% = the dose covering x% of the structure volume, IQR = interquartile range, OARs = organs at risk, PRVcord = the planning organs-at-risk volume of spinal cord,
PTV60 = the sum of the planning target volume of the primary tumor and the metastatic lymph nodes, SIB-IMRT = simultaneous integrated boost intensity-
modulated radiotherapy, SIB-IMRT-D50%: SIB-IMRT with the prescribed dose of 60 Gy delivered to 50% of PTV60, SIB-IMRT-D95%: SIB-IMRT with the prescribed
dose of 60 Gy delivered to 95% of PTV60, Thyroidout of PTV = volume of the thyroid gland excluding the volume overlapping with the PTV60, Vout of PTV = volume of
the body out of all planning target volumes, Vx Gy = the volume receiving x Gy.
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scanned the whole volume of the lung in the dosimetric comparison
between 3DCRT and IMRT. Based on this more appropriate study
design, the present study showed the dosimetric superiority of SIB-
IMRT-D95% compared with 3DCRT in terms of target coverage
and conformality, without increasing the doses to the OARs.
Nevertheless, the present study had limitations. This was a retro-
spective and single-institutional study. The number of included
patients was small. The estimation of toxicity tended to include
some bias. We did not set any dose constraints for the thyroid gland
or the brachial plexus in the optimization of SIB-IMRT. The current
study showed dosimetric advantages of SIB-IMRT-D95% compared
with 3DCRT for this population; however, further study is still
needed to confirm whether SIB-IMRT improves the clinical out-
come for CESCC patients. A multi-institutional Phase II study using
SIB-IMRT for CESCC without hypopharyngeal invasion is ongoing
(UMIN000009880), with a prescribed dose of 60 Gy delivered to
95% of the PTV60. This prospective study will yield important infor-
mation on the effectiveness and safety of definitive chemoradiother-
apy using SIB-IMRT for this population.
In conclusion, upper cervical lymph nodal metastasis was not
observed, and ENI omitting the upper cervical lymph nodal regions
might be a reasonable option for CESCC patients without hypo-
pharyngeal invasion. Though SIB-IMRT-D95% improved target
coverage without increasing the dose to the OARs, compared with
3DCRT, locoregional area remained the major progression site in
CESCC patients treated with SIB-IMRT.
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